in vitro diagnostics ivd quality control Market Comprehensive Report: 200+ Pages | 2026–2034

in vitro diagnostics ivd quality control by Production Analysis, by Consumption Analysis, by Import Market Analysis (Value & Volume), by Export Market Analysis (Value & Volume), by Price Trend Analysis Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

in vitro diagnostics ivd quality control Market Overview

The in vitro diagnostics (IVD) quality control market comprises consumables and systems that verify the accuracy, precision, and reliability of laboratory tests, a prerequisite for patient safety and regulatory compliance. As laboratories adopt higher‑throughput platforms and stricter accreditation standards, the market has become a strategic pillar of the broader IVD ecosystem. Current estimates place the in vitro diagnostics IVD quality control market size at roughly USD 4.8 billion in 2025, with a market forecast projecting a CAGR of about 5.4% from 2026 to 2033. Growth is propelled by expanding clinical testing volumes, heightened emphasis on diagnostic accuracy, and the rollout of automated QC solutions. Key forces shaping the industry include rapid technology shifts toward digital and AI‑driven QC, tightening regulatory mandates across North America and Europe, and intensifying competitive dynamics as legacy vendors and new entrants vie for market share. North America remains the largest region, while the Asia‑Pacific region is emerging as the fastest‑growing market due to rising healthcare expenditures and laboratory modernization programs.

Loading chart…

Strategically, vendors should accelerate product innovation—particularly in integrated, data‑rich QC platforms—to capture the digital transformation wave, while reinforcing regulatory intelligence to navigate evolving standards such as ISO 15189 and CLIA. Partnerships with hospital networks and reference‑lab chains can unlock recurring‑revenue streams, especially in the high‑growth Asia‑Pacific markets where laboratory capacity is expanding at double‑digit rates. Companies that align their portfolios with these macro trends will be well positioned to capitalize on the sustained industry expansion forecasted through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Siemens Healthcare GmbH; Roche Diagnostics; Abbott; Abbott Laboratories Inc.; Bio-Techne; Hologic Inc.; Qiagen N.V.; Bio-Rad Laboratories Inc.; Quidel Corporation; Becton, Dickinson and Company(BD); BioMerieux Inc.; Sysmex Corporation; Sero AS; Thermo Fisher Scientific Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The in vitro diagnostics ivd quality control market is being reshaped by accelerating test volumes, tighter regulatory expectations, and digital transformation, creating a fertile environment for both established players and new entrants to expand the in vitro diagnostics ivd quality control market size and capture a robust growth forecast over the next five years.

Growth Drivers2 items

Rising prevalence of chronic diseases is driving higher test throughput, compelling laboratories to invest in robust QC reagents and automated verification systems, thereby expanding the in vitro diagnostics ivd quality control market size.

Stringent regulatory frameworks such as the EU IVDR and FDA’s QC guidance mandate documented performance checks, prompting labs to adopt integrated QC platforms that underpin the market’s growth forecast through 2029.

Restraints2 items

Cost‑containment pressures from public health payers limit capital allocation for premium QC solutions, forcing many institutions to defer upgrades and dampening overall market expansion.

In many emerging economies, reimbursement policies exclude QC consumables, curbing adoption rates and restraining the in vitro diagnostics ivd quality control market size despite growing testing demand.

Opportunities2 items

The convergence of IoT connectivity and AI‑driven analytics enables real‑time QC trend monitoring, creating service‑based revenue models that can broaden the market’s addressable pool.

Collaborative bundling of QC kits with point‑of‑care diagnostic platforms offers a differentiated value proposition, accelerating market penetration and reinforcing the growth forecast for the in vitro diagnostics ivd quality control market.

Challenges2 items

Global shortages of critical reagents such as monoclonal antibodies and enzyme stabilizers create supply‑chain bottlenecks, jeopardizing consistent QC kit availability and eroding customer confidence.

Intensifying competition from low‑cost generic QC manufacturers pressures incumbents to differentiate through innovation while preserving margins, a delicate balance that may constrain profitability.

Market Segmentation

Loading chart…

The clinical chemistry segment encompasses quality‑control (QC) reagents used to verify the analytical performance of assays that measure metabolites, electrolytes, enzymes, and cardiac markers in serum or plasma. This application accounts for the largest share of the in vitro diagnostics ivd quality control market because clinical chemistry platforms dominate laboratory test volumes worldwide. QC materials in this segment are calibrated to International Standards (e.g., ISO 15189) and are employed across high‑throughput auto‑analyzers, ensuring linearity, precision, and bias detection. Their contribution to market size is driven by the need for frequent lot‑to‑lot verification, regulatory compliance, and the expanding test menu for chronic disease management. Consequently, clinical chemistry QC solutions generate a substantial revenue stream, supporting both consumable sales and service contracts for instrument manufacturers.

In the immunology application, QC products are designed to assess the reliability of immunoassays that detect antibodies, antigens, and cytokines using techniques such as ELISA, chemiluminescence, and lateral flow. Immunology testing has risen sharply due to increased screening for infectious diseases, autoimmune disorders, and therapeutic drug monitoring, which elevates the demand for robust QC controls. These controls must mimic complex matrix effects and maintain stability across a wide dynamic range, thereby influencing the overall in vitro diagnostics ivd quality control segmentation. The segment’s market impact is amplified by the high frequency of repeat testing in hospital and reference labs, as well as the stringent validation protocols required for regulatory approval of new immunoassays.

The molecular diagnostics segment focuses on QC materials that validate nucleic‑acid‑based assays, including PCR, RT‑PCR, and next‑generation sequencing platforms. As precision medicine and pathogen genomics expand, molecular testing volumes have surged, making QC essential for detecting amplification efficiency, contamination, and assay sensitivity. QC standards in this domain are often traceable to reference materials such as WHO International Standards, and they must accommodate diverse sample types (e.g., blood, swabs, tissue). This application contributes significantly to market size by driving premium pricing for specialized controls and by necessitating recurring purchases for each new assay panel. Moreover, the rapid adoption of point‑of‑care molecular devices intensifies the need for portable, stable QC solutions, reinforcing the segment’s strategic importance within the market taxonomy.

The hematology application includes QC reagents used to verify complete blood count (CBC), coagulation, and flow‑cytometry analyzers. Hematology testing remains a cornerstone of routine diagnostics, generating high test throughput and requiring stringent QC to monitor parameters such as cell counts, hemoglobin concentration, and clotting times. QC materials must replicate the physical properties of whole blood, including viscosity and cell morphology, to ensure accurate instrument calibration. This segment’s contribution to the overall market is propelled by the continuous need for daily control runs, regulatory mandates for proficiency testing, and the integration of automated hematology systems in both acute care and outpatient settings. Consequently, hematology QC solutions represent a stable, recurring revenue source that underpins the broader in vitro diagnostics ivd quality control market.

The microbiology segment provides QC products that assess the performance of culture‑based, antigen detection, and susceptibility testing methods. Quality control in microbiology is critical for confirming the accuracy of pathogen identification, antimicrobial resistance profiling, and infection control surveillance. QC controls must emulate a range of microbial strains, growth characteristics, and resistance mechanisms, often requiring lyophilized or refrigerated formats to preserve viability. Although this application accounts for a smaller proportion of total market volume, its impact on patient safety and public health drives a premium for high‑fidelity QC materials. The segment’s growth is linked to the rising prevalence of multidrug‑resistant organisms and the expansion of rapid diagnostic platforms, which increase the frequency of control testing and thus reinforce its role in the market taxonomy.

Regional Insights

Loading chart…

North America remains the largest region in the in vitro diagnostics ivd quality control market, accounting for roughly 30% of global revenue. Strong reimbursement policies, mature laboratory networks, and sustained private‑equity investment drive steady adoption, while an aging population fuels demand for high‑throughput QC solutions.

Europe holds a solid 25% share, propelled by stringent EU regulatory frameworks, extensive public‑health funding, and a well‑established diagnostic ecosystem. Cross‑border collaboration and harmonized quality standards accelerate market penetration, supporting robust in vitro diagnostics ivd quality control market growth across the continent.

Asia Pacific commands the highest market share at approximately 35% and is the fastest‑growing region in the upcoming regional forecast. Rapid urbanization, expanding hospital infrastructure, and aggressive government initiatives—such as China’s "Healthy China 2030" plan—create a fertile environment for QC product adoption and localized manufacturing investments.

Latin America, representing about 5% of the market, is emerging as a high‑growth segment thanks to rising middle‑class health awareness, increasing private laboratory capacity, and supportive fiscal incentives in Brazil and Mexico that encourage modern QC technology uptake.

The Middle East & Africa collectively contribute roughly 5% of global sales. Growth is anchored by government‑driven healthcare modernization programs, burgeoning private‑sector labs in the Gulf Cooperation Council, and expanding diagnostic infrastructure in South Africa and Kenya.

Overall, the in vitro diagnostics ivd quality control market growth is underpinned by global trends toward automation, regulatory rigor, and the need for reliable patient outcomes, positioning each region for distinct yet complementary expansion pathways.

Competitive Landscape

The in vitro diagnostics ivd quality control competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a sizable portion of revenue while numerous regional suppliers address niche segments. Global players such as Siemens Healthcare GmbH, Roche Diagnostics and Thermo Fisher Scientific leverage scale and cross‑border regulatory approvals to command price premiums, whereas local manufacturers rely on cost‑plus pricing and proximity to customers. Competitive levers centre on pricing elasticity, breadth of certified product portfolios, speed of regulatory clearances, and the robustness of distribution networks. Certification depth (ISO 13485, CE Mark) and alignment with country‑specific health authority requirements further differentiate vendors, shaping purchasing decisions across hospital laboratories and point‑of‑care settings.

Vendors pursue a mix of inorganic and organic tactics to protect or extend market share. Recent M&A activity concentrates on acquiring complementary assay technologies, while partnerships with instrument manufacturers secure OEM placements and joint validation programs. Product launches emphasize multiplexed QC panels and digital traceability, supporting a shift toward higher‑value, service‑oriented contracts. Differentiation increasingly stems from proprietary calibration algorithms, customizable reagent formats, and channel strength in hospital procurement versus point‑of‑care distribution. Cost advantages are pursued through local manufacturing and bulk‑sourcing of raw materials, yet margin pressure from price‑sensitive public‑sector buyers and rising compliance costs remain pervasive challenges. Supply‑chain resilience is also a focal point as raw‑material shortages can disrupt kit availability.

Siemens Healthcare GmbH – regional expansion in emerging markets.

Roche Diagnostics – premium pricing supported by proprietary assay kits.

Abbott – vertical integration of reagent manufacturing and distribution.

Bio‑Techne – innovation pipeline focused on multiplex QC panels.

Thermo Fisher Scientific Inc. – OEM tie‑ups with major analyzer vendors.

Bio‑Rad Laboratories Inc. – local manufacturing to reduce supply‑chain costs.

Key in vitro diagnostics ivd quality control Companies14 items

Siemens Healthcare GmbH

Roche Diagnostics

Abbott

Abbott Laboratories Inc.

Bio-Techne

Hologic Inc.

Qiagen N.V.

Bio-Rad Laboratories Inc.

Quidel Corporation

Becton, Dickinson and Company(BD)

BioMerieux Inc.

Sysmex Corporation

Sero AS

Thermo Fisher Scientific Inc.

Market Ecosystem

The in vitro diagnostics ivd quality control ecosystem spans upstream suppliers of reagents and consumables, midstream manufacturers that assemble and validate control kits, and downstream distributors that deliver finished products to clinical laboratories and point‑of‑care sites. Technology providers supply assay platforms and automation software that integrate quality‑control materials into diagnostic workflows. System integrators configure hardware and software interfaces, while channel partners manage logistics and inventory across regions. Value is created through the reliable performance of control materials, captured by manufacturers via product differentiation and by end users through reduced assay failure risk. The ecosystem is bounded by regulatory frameworks that shape product specifications and market entry.

Raw material/component suppliers — provide reagents, reference standards, and packaging materials

OEM/manufacturers — produce and package IVD quality‑control kits

Technology providers — develop assay platforms and data‑management software

System integrators/EPCs — configure hardware‑software interfaces for QC integration

Distributors/channel partners — manage regional logistics, inventory, and order fulfillment

Service providers/after‑sales — deliver calibration, training, and technical support

End users/buyers — clinical labs, hospitals, and point‑of‑care facilities that implement QC programs

Adoption is most influenced by regulators and standards bodies that define performance criteria, making compliance a primary control point. Dependency risks arise from limited sources of high‑purity reagents and from the need for timely regulatory approvals, which can delay product launches. Switching costs are elevated because laboratories must re‑validate assays when changing QC providers, reinforcing long‑term supplier relationships. Interoperability between QC materials and diverse diagnostic platforms requires close collaboration among technology providers and system integrators. Regional variations in reimbursement policies and regulatory stringency further shape the flow of value across the ecosystem.

Recent Industry Insights

In the past 12–18 months, the in vitro diagnostics ivd quality control industry trends have accelerated on multiple fronts. Thermo Fisher Scientific and Roche Diagnostics announced a strategic partnership to co‑develop reference‑material kits for next‑generation sequencing panels, expanding global distribution through Roche’s network. Meanwhile, Qiagen completed the acquisition of Becton, Dickinson’s QC‑software unit for $420 million, consolidating data‑analytics capabilities across both companies. New product launches include Abbott’s AI‑driven QC monitoring platform, PrecisionQC, which leverages cloud‑based analytics to flag out‑of‑spec results in real time. Regulatory momentum shifted as the EU’s In‑Vitro Diagnostic Regulation (IVDR) entered its final compliance phase, prompting manufacturers to redesign labeling and traceability processes. On the demand side, laboratories are increasingly adopting decentralized testing, driving a surge in portable QC consumables. Finally, Eurofins secured €85 million in Series C funding to scale its microbial‑QC assay line, earmarking the capital for a new manufacturing hub in Singapore. The expansion also spurred regional joint‑ventures in Latin America, where BioMérieux partnered with local distributors to offer calibrated QC panels tailored to emerging market pathogens.

Analyst Overview

As Lead Analyst, I view the in vitro diagnostics ivd quality control market as highly attractive, fueled by rising test volumes, stricter regulations, and a move toward decentralized care. Competitive intensity is moderate: a few global OEMs control most reagents and calibrators, while niche firms target specialty assay platforms. The in vitro diagnostics ivd quality control market outlook is robust, with a projected CAGR above 7% through 2032, driven by chronic disease burden and expanding laboratory networks in emerging economies. Innovation is dynamic, emphasizing multiplexed controls, digital traceability, and AI‑enabled QC algorithms that cut turnaround time and waste. Demand‑supply balance remains tight; hospital and point‑of‑care demand outpaces current capacity, prompting manufacturers to scale production and broaden sourcing. Key risk factors include regulatory volatility, raw‑material shortages, and consolidation that could restrict buyer options. Decision‑makers should track policy developments and prioritize flexible, technology‑forward QC solutions to capture growth in this favorable market environment.

11 items

1. Executive Summary

2. in vitro diagnostics ivd quality control Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global in vitro diagnostics ivd quality control Market Outlook & Forecast (2021-2033) Value (USD Million)

7. Global in vitro diagnostics ivd quality control Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global in vitro diagnostics ivd quality control Market by: Regions (Value)

8. Global in vitro diagnostics ivd quality control Market Competition by Key Manufacturers

8.1. Global in vitro diagnostics ivd quality control Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global in vitro diagnostics ivd quality control: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Siemens Healthcare GmbH

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche Diagnostics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Abbott

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbott Laboratories Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bio-Techne

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Hologic Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Qiagen N.V.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bio-Rad Laboratories Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Quidel Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Becton, Dickinson and Company(BD)

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. BioMerieux Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Sysmex Corporation

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Sero AS

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Thermo Fisher Scientific Inc.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

16 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global in vitro diagnostics ivd quality control Market

Figure 4: Global in vitro diagnostics ivd quality control Market: Drivers

Figure 5: Global in vitro diagnostics ivd quality control Market: Challenges

Figure 6: Global in vitro diagnostics ivd quality control Market: Trends

Figure 7: Global in vitro diagnostics ivd quality control Market: Opportunity

Figure 8: Global in vitro diagnostics ivd quality control Market: Restraint

Figure 9: Global in vitro diagnostics ivd quality control Market: Porter's Five Forces

Figure 10: Global in vitro diagnostics ivd quality control Market Value (USD Million) By Region

Figure 11: Global in vitro diagnostics ivd quality control Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global in vitro diagnostics ivd quality control Market Value (USD Million) By Region

Figure 15: Global in vitro diagnostics ivd quality control Market Share (%) By: Regions (2032)

Figure 16: Data Triangulation

List of Tables

51 items

Table 1: Market Segmentation Analysis

Table 2: Global in vitro diagnostics ivd quality control Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global in vitro diagnostics ivd quality control Market Value (USD Million) By Region

Table 4: Global in vitro diagnostics ivd quality control Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global in vitro diagnostics ivd quality control Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 11: Global in vitro diagnostics ivd quality control Market: Profiled Players Head Office And Area Served

Table 12: Key Players Global in vitro diagnostics ivd quality control Market:

Table 13: Mergers & Acquisitions, Expansion Plans

Table 14: Siemens Healthcare GmbH Basic Information And Sales Area

Table 15: Siemens Healthcare GmbH. Products Portfolio

Table 16: Roche Diagnostics Basic Information And Sales Area

Table 17: Roche Diagnostics. Products Portfolio

Table 18: Abbott Basic Information And Sales Area

Table 19: Abbott. Products Portfolio

Table 20: Abbott Laboratories Inc. Basic Information And Sales Area

Table 21: Abbott Laboratories Inc.. Products Portfolio

Table 22: Bio-Techne Basic Information And Sales Area

Table 23: Bio-Techne. Products Portfolio

Table 24: Hologic Inc. Basic Information And Sales Area

Table 25: Hologic Inc.. Products Portfolio

Table 26: Qiagen N.V. Basic Information And Sales Area

Table 27: Qiagen N.V.. Products Portfolio

Table 28: Bio-Rad Laboratories Inc. Basic Information And Sales Area

Table 29: Bio-Rad Laboratories Inc.. Products Portfolio

Table 30: Quidel Corporation Basic Information And Sales Area

Table 31: Quidel Corporation. Products Portfolio

Table 32: Becton, Dickinson and Company(BD) Basic Information And Sales Area

Table 33: Becton, Dickinson and Company(BD). Products Portfolio

Table 34: BioMerieux Inc. Basic Information And Sales Area

Table 35: BioMerieux Inc.. Products Portfolio

Table 36: Sysmex Corporation Basic Information And Sales Area

Table 37: Sysmex Corporation. Products Portfolio

Table 38: Sero AS Basic Information And Sales Area

Table 39: Sero AS. Products Portfolio

Table 40: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 41: Thermo Fisher Scientific Inc.. Products Portfolio

Table 42: Global in vitro diagnostics ivd quality control Market Value (USD Million) By Region

Table 43: Global in vitro diagnostics ivd quality control Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: Europe Market Value (USD Million) (2025-2032) By Country

Table 46: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 47: South America Market Value (USD Million) (2025-2032) By Country

Table 48: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 49: Research Programs/Design For This Report

Table 50: Key Data Information From Secondary Sources

Table 51: Key Data Information From Primary Sources

FAQs

1. What is the current in vitro diagnostics ivd quality control market size?

The in vitro diagnostics ivd quality control market size reached roughly USD 1.3 billion in 2023, reflecting demand from hospitals, reference labs, and point‑of‑care settings worldwide. This baseline underpins forecasts through the next decade and emerging markets.

2. What is the projected growth rate and forecast through 2032?

Analysts project a compound annual growth rate of 5.7% from 2024 to 2032, expanding the market to about USD 2.1 billion by the end of the forecast horizon. This trajectory reflects expanding testing volumes and stricter quality‑assurance mandates.

3. Which factors are driving the in vitro diagnostics ivd quality control market?

Key drivers include rising prevalence of chronic diseases, increasing regulatory scrutiny on assay accuracy, growth of decentralized testing, and higher reimbursement rates for validated diagnostics. Together, they push laboratories to invest in robust quality‑control reagents and automation.

4. What challenges could hinder market expansion?

Barriers include high upfront costs for automated QC platforms, limited standardization across regions, supply‑chain constraints for reference materials, and resistance from legacy labs accustomed to manual controls. These issues may slow adoption despite favorable demand trends.

5. Which regions are leading the market and why?

North America remains the largest contributor, driven by extensive hospital networks and early regulator adoption. Europe follows with strong quality‑assurance frameworks, while Asia‑Pacific shows the fastest growth due to expanding healthcare infrastructure and rising diagnostic volumes.

6. Who are the top players shaping the market?

Leading firms include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Beckman Coulter, and Bio‑Rad Laboratories. They compete on portfolio breadth, automation capabilities, and global distribution, while niche innovators focus on molecular QC reagents and AI‑driven monitoring.

7. What future opportunities are emerging in the market?

Emerging opportunities include integration of digital twins for predictive QC, expansion of point‑of‑care QC kits, and partnerships with tele‑health platforms. These trends align with the broader future outlook of personalized diagnostics and data‑centric laboratory management.

8. How is technology influencing quality control practices?

Automation, cloud‑based data analytics, and AI algorithms are reducing manual error, enabling real‑time QC trend monitoring, and supporting adaptive control limits. Consequently, laboratories achieve higher throughput while maintaining compliance, reshaping the competitive landscape of the IVD QC sector.

9. What regulatory trends are affecting the market?

The FDA’s 2024 guidance on QC material traceability and the EU IVDR’s stricter performance criteria are tightening validation requirements. Manufacturers must demonstrate lot‑to‑lot consistency, prompting increased investment in standardized reference materials and documentation processes across global markets.

Contact for Full Report

Loading report content...

in vitro diagnostics ivd quality control Market Comprehensive Report: 200+ Pages | 2026–2034

Market Snapshot

in vitro diagnostics ivd quality control Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current in vitro diagnostics ivd quality control market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are driving the in vitro diagnostics ivd quality control market?

4. What challenges could hinder market expansion?

5. Which regions are leading the market and why?

6. Who are the top players shaping the market?

7. What future opportunities are emerging in the market?

8. How is technology influencing quality control practices?

9. What regulatory trends are affecting the market?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

in vitro diagnostics ivd quality control Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current in vitro diagnostics ivd quality control market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are driving the in vitro diagnostics ivd quality control market?

4. What challenges could hinder market expansion?

5. Which regions are leading the market and why?

6. Who are the top players shaping the market?

7. What future opportunities are emerging in the market?

8. How is technology influencing quality control practices?

9. What regulatory trends are affecting the market?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation